GINGERA MIDLIFE, UNDERSTOOD
← The reading room
Reproductive health · 11 MIN READ

POI and Early Menopause: A New Paradigm for Long-Term Hormone Care

Full original restored

Ovarian insufficiency before 40 calls for a plan for bone health, fertility, cardiovascular health and emotional support.

Editorial image
In this article
Complete manuscript restored from the archive, with a full English translation. Original medical claims have been preserved for review; medical and regional terminology review remain pending. This is educational reading, not individual medical advice.

Publication identification: Benedetto C, Khadilkar SS, Nappi RE, Genazzani AR, Frezet F, Cucinella L, Divakar H, Anagnostis P, Panay N. Hormone therapy (HT) in women with premature ovarian insufficiency or early menopause: Time to think of a new paradigm for healthy aging. A joint FIGO and IMS position paper. Int J Gynaecol Obstet. 2026;175(1):26-47. DOI: 10.1002/ijgo.71217 Intended audience: clinician readers and women over 40 who follow this publication; this is an academic interpretation/evidence review, not diagnosis, treatment, or a product recommendation. Terminology: international publications often use HT/HRT for menopausal hormone therapy; this publication consistently uses MHT (menopausal hormone therapy), retaining HT when quoting the source.


Executive Summary

In 2026, the International Federation of Gynecology and Obstetrics (FIGO) and the International Menopause Society (IMS) published a joint position paper, signed by nine authors including Nick Panay, proposing a paradigm shift:

POI and early menopause should no longer be viewed as "ordinary menopause happening early," but redefined as chronic endocrine conditions and sentinel events for accelerated aging in women. MHT should be repositioned from "symptomatic relief" to "hormone replacement to prevent long-term disability."

The paper also calls for timely initiation, adequate doses, and sustained long-term MHT to become the foundation of care for POI/early menopause, integrated with lifestyle prevention and multidisciplinary care.

Original article illustration

Old Town riverbank, Porvoo, Finland | Photography:

kallerna

,

CC BY-SA 3.0

This article provides a professional interpretation at five levels: why a new paradigm is needed, what the evidence shows, how diagnosis is changing, how treatment should be reframed, and how this connects with the Chinese context.


1. Background: Why a "New Paradigm" Is Necessary and Urgent

1.1 Systemic Shortcomings in Current Practice

The position paper identifies three major problems with MHT use among people with POI/early menopause: - Fragmented: specialties work separately, without a life-course perspective; - Delayed: treatment often begins only when symptoms become intolerable, missing the window for bone and cardiovascular protection; - Paradigm mismatch: the framework for "older postmenopausal populations" is applied excessively, especially the outdated doctrine of the "lowest dose for the shortest time," leaving younger patients systematically undertreated.

1.2 The Central Proposition: Duration of Exposure Determines the Health Cost

Compared with menopause at the usual age, POI/early menopause causes a longer duration of estrogen deficiency. This "earlier and prolonged" deficiency is associated not only with a shorter lifespan, but also with a reduced healthspan: more years lived with disease and earlier disability.

FIGO/IMS therefore describes intervention for POI/early menopause as "one of the most actionable opportunities to reduce long-term disability and promote healthy aging."


2. A Gradient of Definitions and the "Duration of Exposure" Hypothesis

2.1 Three Age Categories (Position Paper, Table 1)

Condition Age at loss of ovarian function Biological characteristics Expected healthspan trajectory
POI <40 years Sudden or intermittent ovarian insufficiency; longest exposure to estrogen deficiency; occurs during a critical period for bone and cardiopulmonary metabolic health Earlier onset of long-term disease; increased lifetime risk of osteoporosis/fracture, diabetes, arterial hypertension, CVD, neurocognitive/psychological disease, frailty, and disability ↑
Early menopause (EM) 40–44 years (strict IMS definition) Ovarian function ceases earlier than expected; intermediate duration of deficiency Higher risks than menopause at the usual age of osteoporosis/fracture, diabetes, hypertension, CVD, dementia, and frailty ↑; greater disability burden in later life
Menopause at the usual age 45–55 years Gradual ovarian aging; shorter exposure to deficiency Disease and disability concentrated later in life; better balance between lifespan and healthspan

Original article illustration

Saksun village, Faroe Islands | Photography:

MiroRosa

,

CC BY-SA 4.0

Definition note: IMS strictly limits EM to ages 40–44, with POI occurring before 40. Clinicians often use "early menopause" more broadly for menopause before 45. The "before age 45" definition used in this publication's earlier articles on perimenopausal age criteria and premature ovarian insufficiency is the broader definition and does not conflict with the strict IMS definition. Consider the context when citing it.

2.2 Mechanistic Hypothesis: How Estrogen Deficiency "Accelerates Aging"

The position paper directly links POI/EM with accelerated biological aging through mechanisms including: - Epigenetic aging and telomere shortening; - Accelerated vascular aging, particularly in "spontaneous" POI, which may be driven by vascular aging and differ biologically from iatrogenic POI; - Earlier bone loss and shifts in lipid and glucose metabolic homeostasis.

This hypothesis elevates "age at cessation of ovarian function" from a purely reproductive event to a variable regulating the pace of systemic aging.


3. Long-Term Health Risks: A Review of Systemic Evidence

3.1 Skeletal System

  • Untreated POI carries a fracture risk 1.5–3 times that of women with menopause at the usual age (PMC9490892).
  • BMD measurement by DXA should be considered at diagnosis; bone loss has already begun in younger adulthood.
  • Adequate MHT (transdermal E2, 100 μg/day) can restore lumbar spine and femoral neck BMD to normal levels (Dama Newsletter's account of the position paper's evidence).

3.2 Cardiovascular System

  • POI/EM is associated with increased CVD and arterial hypertension risk. In Turner syndrome, high-dose E2 shows dose-dependent benefits for carotid intima-media thickness, a surrogate for CVD; confirmation in other causes of POI is still needed.
  • Accelerated vascular aging may be a central biological feature of "spontaneous" POI.

3.3 Metabolic System

  • Risks of type 2 diabetes and insulin resistance are elevated; a Western dietary pattern may accelerate ovarian functional decline (PMC13417683).

Original article illustration

A street in Tórshavn, Faroe Islands | Photography:

Vincent van Zeijst

,

CC BY-SA 3.0

3.4 Neurocognition

  • Increased risk of cognitive decline and dementia; estrogen deficiency directly affects cerebral glucose metabolism, neuroplasticity, and sleep architecture, echoing this publication's "brain fog does not equal dementia" discussion.

3.5 Psychological and Sexual Health

  • Depression/anxiety occurs at approximately twice the rate in women of the same age;
  • Genitourinary syndrome of menopause (GSM), reduced desire, and low androgen levels, assessed with sensitive testosterone testing, may contribute to sexual dysfunction. Evidence and long-term safety data for testosterone therapy in POI are insufficient, so it is not routinely recommended (RACGP interpretation).

3.6 Frailty and Disability

  • Reduced healthspan and a greater later-life disability burden are the practical implications of the "sentinel event" proposition.

Table 2. Summary of Long-Term Risks (Position Paper and Publicly Available Reviews)

System Main risks Relative increase/key points
Skeletal Osteoporosis and fractures Fracture risk 1.5–3×; early BMD decline
Cardiovascular CVD, hypertension, arterial aging Accelerated vascular aging in spontaneous POI
Metabolic Type 2 diabetes and insulin resistance Risk ↑
Neurocognitive Cognitive decline and dementia Risk ↑
Psychological Depression and anxiety ≈2× age-matched women
Sexual health GSM and impaired desire/function Ask proactively
Overall Frailty, disability, and reduced healthspan ↓ Central proposition

4. Updates to the Diagnostic Framework

4.1 Diagnostic Thresholds: A More Pragmatic Approach

The position paper simplifies the diagnostic threshold: - FSH >25 mIU/mL in someone under 40 with irregular periods or amenorrhea for ≥4 months satisfies the main criteria; - Repeat testing is necessary only when diagnostic uncertainty remains, simplifying the traditional requirement for two tests more than 4 weeks apart.

Difference from Chinese consensus: the 2023 Expert Consensus on Clinical Diagnosis and Treatment of Premature Ovarian Insufficiency (Chinese Journal of Obstetrics and Gynecology, 58(10)) still requires two FSH values >25 more than 4 weeks apart to exclude a transient increase. A suggested clinical approach is that one elevated result plus a typical history can establish high suspicion and initiate assessment, while two repeat assessments remain advisable for a secure diagnosis, especially when making long-term MHT decisions.

4.2 Expanded Etiological Screening

  • Genetic/familial: having a first-degree relative with POI increases one's own risk by approximately 18 times; causes include Turner syndrome, the most common chromosomal cause, the fragile X (FMR1) premutation, and galactosemia.
  • Autoimmune: 21-hydroxylase antibodies are the most specific marker for screening spontaneous POI; assess for Hashimoto thyroiditis, Addison disease, and type 1 diabetes.
  • Genomic advances: standard karyotyping plus FMR1 testing misses most genetic drivers. If baseline findings are negative but the family history is strong, the position paper recommends next-generation sequencing (NGS) and whole-exome sequencing (WES).
  • Iatrogenic: chemotherapy, radiotherapy, and pelvic surgery directly damage the follicle pool.

Original article illustration

Helsinki Cathedral, Finland | Photography:

Old Pionear

,

CC BY-SA 4.0

Table 3. Risk Factors (Epidemiology; Selected from Position Paper, Table 2)

Category Representative factors
Genetic Family history of POI, 18× for first-degree relatives; Turner syndrome; fragile X; monogenic syndromes
Comorbidities Autoimmune disease, history of radiotherapy/chemotherapy or pelvic surgery, galactosemia
Lifestyle BMI <18.5, smoking, exposure to endocrine disruptors
Early life Multiple pregnancy, preterm birth, intrauterine tobacco exposure, short duration of breastfeeding
Reproductive Early menarche, <11 years; cycles <25 days
Infection Mumps, tuberculosis, HIV

5. Reframing Treatment: From "Symptom Relief" to "Healthspan Protection"

5.1 Adequate Dosing: The Goal Is "Physiological Replacement," Not the "Lowest Effective Dose"

  • Goal: restore serum estradiol to 50–100 pg/mL, a physiological premenopausal range.
  • The position paper and contemporary interpretations emphasize that POI/EM often requires approximately twice the standard postmenopausal MHT dose (Dama Newsletter, "double the dose"), with a proportionate increase in progestogen to protect the endometrium.
  • The ESHRE 2024 international guideline gives reference doses for ages 16–50 of transdermal estradiol 75–100 μg/day, or oral E2 2–4 mg/day.

Table 4. Estradiol (E2) Regimen Doses (Position Paper, Table 3, Combined with ESHRE 2024)

Formulation Common dose
Transdermal patch 75–100 μg/day
Transdermal gel, sachets 2–3 mg/day
Transdermal gel pump, 0.75 mg/actuation 3–4 actuations/day
Transdermal spray, 1.53 mg/spray 3–4 sprays/day
Oral E2 2.0–4.0 mg/day, continuous regimen

5.2 Adequate Duration: Continue Until the Average Age of Menopause, Then Individualize

  • MHT should continue at least until the average age of natural menopause, approximately 50–51, before transitioning to the postmenopausal MHT framework.
  • Avoid the "shortest time" dogma; symptom control and long-term protection should guide shared decisions between patient and doctor.

Original article illustration

Gamla Stan, Stockholm, Sweden | Photography:

Richardmaackphotography

,

CC BY 4.0

5.3 Route of Administration: Prefer Transdermal Treatment

  • Transdermal estradiol is preferred in those at risk of VTE, migraine, or liver disease because it avoids hepatic first-pass metabolism and has a lower thrombotic risk, consistent with the "transdermal first" principle in this publication's earlier Report G.

5.4 Endometrial Protection: An Adequate Progestogen Dose and Duration

  • Those with a uterus must receive a progestogen: micronized progesterone, dydrogesterone, MPA, or a levonorgestrel intrauterine system (LNG-IUS), which avoids systemic adverse effects of oral progestogens.
  • Increase the progestogen dose proportionately as E2 increases.

5.5 When Systemic MHT Is Contraindicated: Maintain Active Long-Term Care

  • A contraindication, such as a hormone-sensitive tumor, does not mean abandoning long-term care. Focus on lifestyle optimization, CVD risk reduction, bone protection, and individualized symptomatic care for vasomotor and genitourinary symptoms.

6. Integrated Multidisciplinary Care: A Life-Course Model

The position paper recommends integrating care through a life-course model: - Reproduction/fertility: refer promptly to a reproductive center if fertility is a priority at diagnosis; embryo/oocyte/ovarian tissue cryopreservation, echoing the Ruan Xiangyan team's IMS 2026 findings. - Bone: baseline DXA, calcium plus vitamin D, and weight-bearing exercise. - Cardiometabolic health: monitor blood pressure, lipids, and glycated hemoglobin. - Psychological health: depression/anxiety screening and referral. - Sexual health: proactively ask about GSM and sexual function; vaginal estrogen/lubricants. - Endocrine/immune health: manage coexisting autoimmune disease.


7. The Economic Argument: Why "Starting Early" Also Makes Sense for Health Systems

A contemporary US health economic analysis from 2026 (Gill et al., as reported in Dama Newsletter, the first since 2009) found: - Early MHT initiation could save insurers as much as US$135 million over a lifetime per 10,000 patients; - Extrapolated nationwide savings exceeded US$216 billion, primarily through avoiding chronic conditions such as fractures, CVD, and metabolic disease.

This provides a health-economic argument for viewing "MHT as preventive investment rather than consumption."


8. Connections with the Chinese Context

  • Agreement between consensuses: the 2023 Chinese Expert Consensus on Clinical Diagnosis and Treatment of Premature Ovarian Insufficiency already specifies "start as early as possible after excluding contraindications; continue until the average age of natural menopause, around 50; use standard or slightly higher doses; prefer transdermal treatment; protect the endometrium; and follow up annually." This closely aligns with FIGO/IMS 2026.
  • A highlight from China: at IMS 2026, Professor Ruan Xiangyan's team at Beijing Obstetrics and Gynecology Hospital presented ovarian tissue cryopreservation, with over 1,000 cases stored and 72 transplants all successful, including the world's first live birth after transplantation in a colorectal cancer patient. This offers a Chinese approach to preventing and treating iatrogenic POI internationally.
  • Connection to this publication's earlier reports: our In-Depth Research Report on Premature Ovarian Insufficiency (POI), October 2026, already covered definitions, diagnosis, causes, seven MHT principles, scams, and long-term risks. This article adds the 2026 FIGO/IMS paradigm shift, a pragmatic diagnostic approach, the "double dose" target, upgraded NGS/WES screening, and health-economic arguments.

Original article illustration

Tromsø harbor, Norway | Photography:

Godot13

,

CC BY-SA 4.0


9. Implications for Clinical Communication: A Shared Decision-Making Framework

  • Replace the old narrative of "POI diagnosis = lifelong estrogen deficiency and a bleak prognosis" with a shared decision-making framework of "a manageable chronic condition plus a retained fertility window." This can substantially reduce anxiety and resistance to treatment, as already proposed in this publication's Report G.
  • Key communication points: (1) estrogen deficiency is a systemic event, not solely a reproductive one; (2) MHT aims to replace missing physiological hormones and offset long-term disability, not provide "extra nourishment"; (3) continuing until around 51 follows a protective rationale rather than creating dependence; (4) long-term management pathways also exist when MHT is contraindicated.

10. Research Priorities: The FIGO/IMS Call

  1. Better characterization of causes, particularly genetic and epigenetic factors;
  2. Global registries and research into treatment adherence;
  3. RCT evidence on optimal MHT regimens, including formulation, dose, and duration;
  4. Prospective cohorts examining long-term health outcomes in POI/EM.

11. Restating the Boundaries

  • This is an academic, evidence-based interpretation of the FIGO/IMS 2026 position paper, ESHRE 2024 guideline, 2023 Chinese expert consensus, and contemporary publications.
  • It does not constitute diagnosis, treatment advice, or a product recommendation. Specific MHT formulations, doses, routes, and follow-up must be determined by the treating physician, considering individual thrombosis, breast, and CVD risks; liver and renal function; whether the uterus is present; and other factors.
  • The focus remains the right to information plus bringing records to shared decision-making with the treating physician.

References: Key Sources

  1. Benedetto C, Khadilkar SS, Nappi RE, et al. Hormone therapy (HT) in women with premature ovarian insufficiency or early menopause: Time to think of a new paradigm for healthy aging. Int J Gynaecol Obstet. 2026;175(1):26-47. DOI: 10.1002/ijgo.71217. (Joint FIGO/IMS position paper.)
  2. Guideline Central. FIGO/IMS Hormone Therapy in Women with POI or Early Menopause Guideline Summary. 2026-08-18 / updated 2026-09-22.
  3. Dama Health. The Paradigm Shift: From Symptom Management to Healthspan Preservation (Aug 2026 Newsletter); citing Gill et al.'s 2026 health economic analysis and Benedetto et al. 2026.
  4. Premature ovarian insufficiency: Updated concepts in diagnosis and hormonal treatment strategies. PMC12396276 (includes the ESHRE 2024 dose table).
  5. Menopause management: A manual for primary care practitioners. PMC9490892 (fracture risk 1.5–3×).
  6. The role of diet in the pathogenesis and management of POI. PMC13417683.
  7. Premature ovarian insufficiency in general practice. RACGP / Australian Menopause Society interpretation.
  8. 2023 Expert Consensus on Clinical Diagnosis and Treatment of Premature Ovarian Insufficiency. Chinese Journal of Obstetrics and Gynecology 58(10).
  9. Shanghai Municipal Health Commission. Take These Three Steps to Prevent "Premature Ovarian Insufficiency." 2024-08-14.
  10. Beijing Municipal Health Commission. Professor Ruan Xiangyan's Team at Beijing Obstetrics and Gynecology Hospital Presents New Technologies for Preventing and Treating Premature Ovarian Insufficiency to the World. 2026-10-09 (Chinese findings at IMS 2026).

(Written on 2026-10-27 for academic and health education topic planning; follow your doctor's guidance for individual diagnosis and treatment.)

SOURCE NOTES

Read the source material

The original archive manuscript is restored above. These additional references offer context; their inclusion does not constitute medical validation of every original claim. Clinical and regional terminology review are pending.

GINGERA / COMMUNITY

A good question starts a conversation.

Explore a related editorial discussion. Reading is open to everyone; posting and replying require a free reader account.

Create a free accountDiscuss care across borders